The superior survival seen among patients with Hodgkin Lymphoma treated in clinical trials can be largely explained by the differences in baseline characteristics, particularly younger age, 20 year results from the EORTC-Netherlands cancer registry show. People with Hodgkin lymphoma who were treated as part of a clinical trial had an 8% superior crude 10-year overall survival compared ...
Improved clinical trial survival rates in HL explained by age
By Nicola Garrett
31 Oct 2016